Longeveron LLC (LGVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.22M
Last updated: Nov 17, 2026 at 4:10 PM ET
Longeveron LLC (LGVN) Statistics
Longeveron LLC (LGVN) has a market cap of $7.22M. Its share count is up 1647.72% from a year earlier. It kept -1921.72% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $7.22M |
|---|---|
| Latest price (Nov 17, 2026) | $2.11 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.8x and 1.4x. Its year-end P/S ranged from 35.2x to 553.0x from 2022 to 2025.
| P/S Ratio | 5.8x |
|---|---|
| Forward P/S | 4.1x |
| P/B Ratio | 1.4x |
| P/TBV Ratio | 2.7x |
Price Statistics
The stock is down 69.05% over 52 weeks and trades 22.99% below its 50-day average.
| Beta (1Y) | 0.79 |
|---|---|
| 52-Week Change | -69.05% |
| 1-Month Change | +51.80% |
| 3-Month Change | -74.34% |
| 6-Month Change | -68.66% |
| 5-Year Change | -99.52% |
| Total Return (1Y) | -69.05% |
| Total Return (3Y CAGR) | -77.68% |
| Total Return (5Y CAGR) | -68.59% |
| Return vs SPY (1Y) | -78.59% |
| Max Drawdown (1Y) | -88.02% |
| Max Drawdown (3Y) | -99.41% |
| Sharpe Ratio (1Y) | -0.79 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $2.74 |
| 200-Day Average | $6.43 |
| 52-Week Range | $1.31 to $12.30 |
| RSI (14 Days) | 46.2 |
| Average Volume (20 Days) | 100.27K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.25x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.25x |
|---|---|
| Quick Ratio | 1.25x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -475.33% and return on assets is -186.33% over the last 12 months.
| Return on Equity (ROE) | -475.33% |
|---|---|
| Return on Assets (ROA) | -186.33% |
| Return on Capital Employed (ROCE) | -407.94% |
| Asset Turnover | 0.08x |
| Receivables Turnover | 18.06x |
Scores
LGVN has an Altman Z-Score of -22.72, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -22.72 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.17M over the last 12 months is down 18.93% from the 12 months before.
| Revenue | $1.17M |
|---|---|
| Revenue Growth (YoY) | -18.93% |
| Gross Profit | $774.00K |
| Operating Income | -$23.54M |
| Pretax Income | -$22.39M |
| Net Income | -$22.39M |
| EBITDA | -$21.41M |
| EBIT | -$22.39M |
| Reported EPS (TTM) | -$4.49 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 39.18% of the $12.02M in total assets.
| Cash and Equivalents | $7.25M |
|---|---|
| Total Debt | $0 |
| Net Cash | $7.25M |
| Net Cash Per Share | $2.26 |
| Working Capital | $1.62M |
| Shareholder Equity | $4.71M |
| Book Value Per Share | $1.47 |
| Tangible Book Value | $2.54M |
| Tangible Book Per Share | $0.79 |
| Total Assets | $12.02M |
| Total Liabilities | $7.30M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $232.00K of capital spending, operating cash flow left -$18.24M of free cash flow.
| Operating Cash Flow | -$18.01M |
|---|---|
| Capital Expenditures | $232.00K |
| Free Cash Flow | -$18.24M |
| FCF Per Share | -$5.99 |
| Depreciation and Amortization | $977.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2020.77%.
| Gross Margin | 66.44% |
|---|---|
| Operating Margin | -2020.77% |
| Pretax Margin | -1921.72% |
| Net Margin | -1921.72% |
| EBITDA Margin | -1837.85% |
| EBIT Margin | -1921.72% |
| FCF Margin | -1565.58% |
| Gross Margin (5Y Average) | 52.55% |
Growth
Revenue fell 0.63% a year over 3 years.
| Revenue Growth (3Y CAGR) | -0.63% |
|---|---|
| Revenue Growth (5Y CAGR) | -26.60% |
| Book Value Per Share Growth (2Y CAGR) | -70.67% |
| Tangible Book Per Share Growth (2Y CAGR) | -72.11% |
Dividends and Yields
LGVN does not pay a dividend. Its free cash flow yield is -268.25%.
| FCF Yield | -268.25% |
|---|---|
| Buyback Yield | -32.44% |
| Shareholder Yield | -32.44% |
Stock Splits
The last split was a 1-for-10 reverse split on Aug 27, 2026.
| Last Split Date | Aug 27, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Analyst Forecast
Consensus estimates put revenue growth at 34.96% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +34.96% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LGVN
What is LGVN's market cap?
Longeveron LLC has a market cap of $7.22M.
How many shares of LGVN are outstanding?
Longeveron LLC has 3.21M shares outstanding. The count is up 1647.72% from a year earlier.
Does LGVN pay a dividend?
No. Longeveron LLC does not pay a dividend.
How much debt does LGVN have?
Longeveron LLC has $0 of total debt and $7.25M of cash and equivalents, a net cash position of $7.25M.
LGVN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors